论文信息 - Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial - 字舞流文

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Bin Zhou | N. Patel | M. Frieman | G. Glenn | Gale Smith | T. Klein | P. Nugent | J. Logue | Michelle Robinson | P. Griffin | E. Athan | Sonia Maciejewski | S. Kitchener | J. Plested | R. Mallory | Holly L. Hammond | C. Lemech | J. Lickliter | M. Turner | Mingzhu Zhu | S. Thackwray | A. Robertson | L. Baracco | N. Formica | Mark D. Adams | Joshua Kim | B. Wilkinson | S. Cloney-Clark | Fiona E Napier‐Flood | G. Albert | Mark Arya | Toby Briskin | G. Chau | A. Marcheschi | H. Mcfall | Susan M Pfeiffer | I. Berger | P. Bradley | Richard Glover II | Amber Leah | I. Leelasena | Mary Beth Manning | Indika Leelasena | M. Arya | James Logue | Bethanie E. Wilkinson | Fiona Napier-Flood | Holly Hammond